Insmed (INSM) Given Daily Media Impact Rating of 0.16

Media stories about Insmed (NASDAQ:INSM) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Insmed earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.535066204237 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s rankings:

Shares of Insmed (INSM) opened at $30.46 on Friday. The firm has a market cap of $2,330.00, a price-to-earnings ratio of -9.76 and a beta of 1.18. Insmed has a 52 week low of $11.49 and a 52 week high of $33.94. The company has a quick ratio of 15.21, a current ratio of 15.21 and a debt-to-equity ratio of 0.13.

A number of research analysts have issued reports on INSM shares. Zacks Investment Research cut shares of Insmed from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price target on shares of Insmed in a report on Monday, November 6th. Cowen reaffirmed a “buy” rating and issued a $54.00 price target on shares of Insmed in a report on Friday, November 3rd. BidaskClub raised shares of Insmed from a “sell” rating to a “hold” rating in a report on Friday, December 22nd. Finally, Robert W. Baird reaffirmed a “positive” rating and issued a $42.00 price target (up previously from $32.00) on shares of Insmed in a report on Thursday. One research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $35.75.

In related news, Director Donald J. Hayden, Jr. sold 15,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $32.50, for a total transaction of $487,500.00. Following the sale, the director now owns 71,131 shares in the company, valued at $2,311,757.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 4.03% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: “Insmed (INSM) Given Daily Media Impact Rating of 0.16” was first posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.tickerreport.com/banking-finance/3126298/insmed-insm-given-daily-media-impact-rating-of-0-16.html.

About Insmed

Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).

Insider Buying and Selling by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.